Expand all sections

Pembrolizumab

Keytruda

Extended indication Keytruda als monotherapie is geïndiceerd als adjuvante behandeling bij volwassenen met stadium III-m
Therapeutic value Possible added value
Total cost 56,686,200.00
Registration phase Registered and reimbursed

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information